<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17289" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Agitation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Naveen P.</given-names>
          </name>
          <aff>University of Michigan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huecker</surname>
            <given-names>Martin R.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Naveen Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Martin Huecker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17289.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Agitation is a complex, nonspecific constellation of behaviors observed in various treatment settings. Agitation can pose significant risks to both the agitated individuals and those around them, making it an emergency. Acute presentations of agitation can include restlessness, inability to stay calm, paranoia, suspiciousness, irritability, hostility, confusion, disorientation, inability to communicate, changes in vital signs, and violent behavior. The etiology of agitation is multifactorial and includes neurological, infectious, cardiac, respiratory, psychiatric, toxic or metabolic, endocrine, constitutional, and substance-related causes.&#x000a0;The approach to understanding and managing agitation varies based on the setting, individual factors, clinician's experience, and specific etiology.&#x000a0;</p>
        <p>Early assessment should include point-of-care glucose, oxygen saturation, and urine toxicology screen.&#x000a0;Effective management prioritizes diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment. Treatment strategies are guided by the specific etiology of agitation and the epidemiology of the local patient population, which may include understanding the prevalence of substance use in the community.&#x000a0;This activity reviews the current understanding of the neurobiology of agitation, various causes of behavioral disturbances, diagnostic cues, and management strategies across different settings. This activity also explores&#x000a0;the etiology, pathophysiology, risk factors,&#x000a0;early assessment, and principles of treatment for this complex condition. This activity highlights the role of the interprofessional healthcare team in managing agitation and&#x000a0;provides them with the knowledge necessary to provide optimal care for individuals with agitation, as mismanagement can lead to poor patient outcomes and staff injuries.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms of agitation and recognize its multifactorial etiology, including neurological, psychiatric, and substance-related causes.</p></list-item><list-item><p>Implement effective de-escalation techniques and pharmacological interventions tailored to the specific etiology of agitation to ensure patient and staff safety.</p></list-item><list-item><p>Apply knowledge of the neurobiology of agitation and current management guidelines to provide evidence-based care and improve patient outcomes.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team, including psychiatry, nursing, and security, to manage agitation comprehensively and safely.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17289&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17289">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17289.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Agitation is a nonspecific constellation of behaviors seen in various treatment settings. Agitated individuals can be dangerous to themselves and others, making agitation an emergency. Acute presentations of agitation can include restlessness, inability to stay calm, paranoia, suspiciousness, irritability, hostility, confusion, disorientation, inability to communicate, changes in vital signs, and violent behavior.&#x000a0;Agitation can have a multifactorial etiology that is often difficult to identify. Individuals with agitation may present in various settings, including emergency departments, medical units, intensive care units (ICUs), inpatient psychiatry units, outpatient clinics, and long-term care facilities. Approaches to understanding and managing agitation can vary depending on the setting, individual factors, clinician experience, and the underlying etiology.&#x000a0;</p>
        <p>Multiple definitions have been offered for agitation, reflecting the complexity of this syndrome. The <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders,</italic> 5th ed.;<italic toggle="yes">&#x000a0;</italic>Text Revision (<italic toggle="yes">DSM-5-TR</italic>)&#x000a0;characterizes agitation as "the inability to sit still, pacing, handwringing; or pulling or rubbing of the skin, clothing, or other objects" and as "disruptive motor or vocal activity." In their evaluation of a new drug application for the treatment of agitation on May 11, 2023, the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research described agitation as including "symptoms ranging from pacing and restlessness to verbal and physical aggression." The International Experts' Meeting on Agitation in 2016 noted that&#x000a0;a consensus on the definition of agitation does not exist and formulated a practical description of agitation as "a&#x000a0;state where patients cannot remain still or calm, characterized by internal features such as hyperresponsiveness, racing thoughts, and emotional tension; and external ones, mainly motor and verbal hyperactivity, and communication impairment."&#x000a0;<xref ref-type="bibr" rid="article-17289.r1">[1]</xref><xref ref-type="bibr" rid="article-17289.r2">[2]</xref>&#x000a0;In dementia, it is helpful to conceptualize aggressive and agitated behavior as "<italic toggle="yes">responsive behavior</italic> that manifests in response to a stimulus in the patient's internal or external environment."&#x000a0;<xref ref-type="bibr" rid="article-17289.r3">[3]</xref></p>
        <p>Agitation can be distinguished from aggression. In individuals with dementia, agitation is described as "a constellation of symptoms, including pacing, aimless wandering, performing repetitious mannerisms, and general restlessness," whereas aggression encompasses "both verbal and physical behavior, such as hitting, kicking, pushing, throwing or tearing things, spitting, biting, scratching, destroying property, grabbing people or objects away from others, hurting oneself or others, making sexual advances, cursing, and screaming."&#x000a0;<xref ref-type="bibr" rid="article-17289.r3">[3]</xref>&#x000a0;In the broader population, acute agitation is characterized as "a state of unease or inner tension with or without excessive motor activity," while aggression is the "behavioral expression of severe agitation with the potential to cause harm to oneself or others."&#x000a0;<xref ref-type="bibr" rid="article-17289.r4">[4]</xref>&#x000a0;As the definition and use of the term "agitation" vary, the clinical team should attempt to identify patient-specific behaviors to clarify how agitation is defined for each individual patient. Reaching a consensus on this definition will help direct the management plan effectively.<xref ref-type="bibr" rid="article-17289.r3">[3]</xref>&#x000a0;</p>
        <p>In a study of patients with dementia, aggressive behavior was defined as "an overt act involving the delivery of noxious stimuli to (but not necessarily aimed at) another object, organism, or self, which is clearly not accidental."&#x000a0;<xref ref-type="bibr" rid="article-17289.r5">[5]</xref>&#x000a0;In this population, the prevalence of verbal aggression was 89%, while physical aggression and destructive behavior were 61% and 25%, respectively. Verbal aggression was found to persist for about 2 years, and 67% of individuals with verbal aggression remained verbally aggressive until near death. Physical aggression was found to be self-limiting, lasting for only 1 year. Intimate care was identified as the primary factor precipitating aggressive behavior, with hallucinations and delusions as secondary contributors.<xref ref-type="bibr" rid="article-17289.r5">[5]</xref>&#x000a0;</p>
        <p>The proposed hypothesis for this association is that misinterpretation of the environment leads to the perception of intimate care as a threat. This hypothesis is supported by the finding that most aggressive behavior was directed toward a group, primarily primary caregivers. Aggressive behavior resembled the patient's premorbid behavior (behavior before dementia diagnosis) in only 3% of cases. In contrast, 43% of individuals displayed aggression as an "exaggeration of premorbid behavior," while 53% exhibited aggression that was "quite different from premorbid behavior." Aggressive behavior was found to cease before death, with the hypothesized mechanism being progressive cognitive impairment. This impairment likely leads to reduced awareness of the environment and a diminished perception of intimate care as a threat.<xref ref-type="bibr" rid="article-17289.r6">[6]</xref><xref ref-type="bibr" rid="article-17289.r7">[7]</xref></p>
      </sec>
      <sec id="article-17289.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Agitation can be multifactorial, reflecting the interaction between&#x000a0;precipitating factors and patient characteristics.<xref ref-type="bibr" rid="article-17289.r8">[8]</xref>&#x000a0;In the emergency department, patients may be agitated due to reasons such as intoxication with alcohol or drugs, shock or other metabolic derangements, or exacerbation of psychiatric illness. Quick stabilization is essential to ensure patient and staff safety. In a study, almost 3% of patients presented to the emergency department with agitation, of whom 23% met the criteria for delirium.<xref ref-type="bibr" rid="article-17289.r9">[9]</xref></p>
        <p>The most common conditions that lead to agitation in hospitalized patients are delirium, dementia, and acute psychosis. Delirium develops over a short period, is precipitated by an underlying medical cause or substance intoxication or withdrawal, and is characterized by fluctuations in attention and cognition.<xref ref-type="bibr" rid="article-17289.r10">[10]</xref>&#x000a0;One or several co-occurring medical conditions can cause delirium. Predisposing factors for delirium include male gender, older age, cognitive impairment, and metabolic derangements. Precipitating factors include medications such as anticholinergic or psychoactive substances, surgery, hypoxemia and hypoxia, acute pain, and infection.</p>
        <p>Delirium is classified into 3 types&#x02014;hyperactive, hypoactive, and mixed. Agitation in delirium is primarily associated with the hyperactive and mixed subtypes. These subtypes describe the individual's level of psychomotor activity. In hyperactive delirium, psychomotor activity is increased, while in mixed delirium, it fluctuates between increased and decreased (hypoactive) motor activity.<xref ref-type="bibr" rid="article-17289.r10">[10]</xref></p>
        <p>Differentiating delirium from other neurocognitive disorders, such as Alzheimer disease or related dementias (ADRD), is important,&#x000a0; which are characterized by a gradual worsening of cognitive function. Delirium is characterized by rapidly fluctuating mental status with onset in hours to days, whereas dementia involves a gradual deterioration of cognitive function over months to years. Major neurocognitive disorder from ADRD is specified as with or without behavioral disturbances. When delirium and ADRD are comorbid, priority should be given to managing the delirium.</p>
        <p>Other etiologies of agitation include traumatic brain injury (TBI), physical pain, acute psychosis or mania in schizophrenia or bipolar spectrum disorders, seizure disorders, autism spectrum disorder, anxiety disorders, acute stress disorder, personality disorders, and sleep-wake cycle disruption.<xref ref-type="bibr" rid="article-17289.r11">[11]</xref><xref ref-type="bibr" rid="article-17289.r10">[10]</xref>&#x000a0;Many of these conditions are associated with frontal lobe dysfunction, which is believed to contribute to increased aggressive and agitated behavior.<xref ref-type="bibr" rid="article-17289.r12">[12]</xref><xref ref-type="bibr" rid="article-17289.r13">[13]</xref></p>
      </sec>
      <sec id="article-17289.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The epidemiology of agitation varies by age group,&#x000a0;etiology, environment, and severity.&#x000a0;A&#x000a0;large-scale prospective observational study conducted in an urban county emergency department in 2018 found the prevalence of agitation to be 2.6%. Of these patients, 23% met the criteria for delirium. Additionally, 84% of patients with agitation required physical restraint, and 72% required sedation with an intramuscular injection to allow for medical evaluation and to protect both the patient and medical providers from injury.<xref ref-type="bibr" rid="article-17289.r9">[9]</xref>&#x000a0;</p>
        <p>A study conducted in 2 urban settings in Germany studied the incidence of prehospital psychiatric emergency situations requiring a second-tier response by an emergency physician. In both urban settings, approximately 12% of all cases were psychiatric emergencies.<xref ref-type="bibr" rid="article-17289.r14">[14]</xref>&#x000a0;In&#x000a0;one setting, 22.3% of psychiatric emergency calls were for agitation, while in the other setting, 30.1% of psychiatric emergency calls were for agitation.&#x000a0;Agitation prevalence ranges from 30% to 50% in Alzheimer disease, 30% in Lewy body disease, 40% in frontotemporal degeneration, and 40% in vascular disease. In nursing homes, 80% of residents experience agitation.<xref ref-type="bibr" rid="article-17289.r15">[15]</xref>&#x000a0;A 2018 study in the Netherlands observed the progression of neuropsychiatric symptoms in patients with young-onset dementia, defined as the onset of symptoms before the age of 65, residing in nursing homes. Over the course of 2 years, 52% of young-onset dementia patients developed agitation.<xref ref-type="bibr" rid="article-17289.r16">[16]</xref>&#x000a0;</p>
        <p>The incidence of agitation in the ICU is estimated to be between 17.5% and 72%.<xref ref-type="bibr" rid="article-17289.r17">[17]</xref><xref ref-type="bibr" rid="article-17289.r18">[18]</xref><xref ref-type="bibr" rid="article-17289.r19">[19]</xref>&#x000a0;Agitation&#x000a0;is associated with prolonged ICU stays, mechanical ventilation, unplanned venous catheter removals, unplanned extubations, and nosocomial infections. Independent risk factors for agitation in the ICU include the use of psychoactive drugs at the time of admission, a history of alcohol use disorder, abnormal sodium levels, sepsis, fever, and sedative administration in the ICU.<xref ref-type="bibr" rid="article-17289.r19">[19]</xref>&#x000a0;</p>
        <p>Among patients with bipolar disorder and schizophrenia, a 2018 cross-sectional study conducted in Europe found that the majority of agitation episodes in the prior year were either mild or moderate in intensity (22.4% and 15.4%, respectively).<xref ref-type="bibr" rid="article-17289.r20">[20]</xref>&#x000a0;The&#x000a0;intensity of episodes was characterized through self-report, using a predefined list of symptoms. Two-thirds of patients demonstrated insight and awareness of their agitation. The most commonly reported symptoms during an episode of agitation were feeling uneasy, restlessness, and nervousness.<xref ref-type="bibr" rid="article-17289.r20">[20]</xref></p>
        <p>Between 2007 and 2016, about 8.4 million (8.3%) of 100.9 million emergency department visits in the United States were for psychiatric or substance-use&#x02013;related diagnoses, with the percentage generally increasing over time.<xref ref-type="bibr" rid="article-17289.r21">[21]</xref>&#x000a0;Substance&#x000a0;use is a significant risk factor for agitation. The lifetime prevalence of substance use disorders among patients with bipolar disorder is estimated to be 48% to 61%, and among patients with schizophrenia, it is estimated to be 47%.<xref ref-type="bibr" rid="article-17289.r22">[22]</xref>&#x000a0;The&#x000a0;lifetime prevalence of a substance use disorder in the general community sample of this study was 17%. Substance use, including cannabis, stimulants, opioids, sedatives, and hallucinogens, is independently associated with an increased risk of violent behavior.<xref ref-type="bibr" rid="article-17289.r23">[23]</xref>&#x000a0;This risk has been estimated to be 4 to 10 times higher compared to the general population.</p>
        <p>Agitation is reported in 20% to 41% of patients with TBIs in acute care units during the early recovery period, rising to 70% in rehabilitation settings.<xref ref-type="bibr" rid="article-17289.r24">[24]</xref>&#x000a0;The point prevalence of agitation in patients with intellectual disabilities is reported to be approximately 10%, with a remission rate of 25% at 2 years.<xref ref-type="bibr" rid="article-17289.r25">[25]</xref>&#x000a0;Increased risk of medium to high levels of aggression is associated with factors such as younger age, longer behavioral episodes, psychotropic medication use, pervasive developmental disorder, mood instability and irritability, increased contact with mental health professionals, and the need for home care. Several of these risk factors indirectly reflect the severity of the patient&#x02019;s baseline condition. Personality disorders and&#x000a0;longer length of behavioral episodes are&#x000a0;associated with adverse clinical outcomes, along with agitation during behavioral episodes and more frequent contact with mental health professionals. In contrast, pervasive developmental disorder is associated with improved clinical outcomes.<xref ref-type="bibr" rid="article-17289.r25">[25]</xref></p>
      </sec>
      <sec id="article-17289.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The neuroanatomy and neurophysiology of agitation involve several brain pathways and regions. Positron-emission tomography (PET) scans in patients with personality disorders and anxiety have highlighted frontal lobe dysfunction as a primary contributor to agitation.<xref ref-type="bibr" rid="article-17289.r26">[26]</xref><xref ref-type="bibr" rid="article-17289.r27">[27]</xref>&#x000a0;Restlessness has been associated with disturbances in the limbic and striatal sensorimotor pathways, which leads to the excitation of prefrontal and sensorimotor cortices and the subsequent motor expression of restlessness in the form of agitation.<xref ref-type="bibr" rid="article-17289.r28">[28]</xref>&#x000a0;This bottom-up activation occurs in the setting of insufficient top-down&#x000a0;inhibition and&#x000a0;control normally exerted by higher cortical regions.<xref ref-type="bibr" rid="article-17289.r29">[29]</xref>&#x000a0;</p>
        <p>Insufficient amygdalar modulation by higher cortical regions and subsequent hyperactivity can lead to overestimating threats and misinterpreting environmental stimuli. External stress can contribute to the activation of these pathways by reducing inhibition from the prefrontal cortex. Additionally, disordered modulation between the prefrontal cortex and the locus coeruleus locus coeruleus has also been implicated, leading to increased&#x000a0;tonic activity of the locus coeruleus and subsequent increased norepinephrine release.<xref ref-type="bibr" rid="article-17289.r29">[29]</xref>&#x000a0;</p>
        <p>Dementia may also lead to overactivity of norepinephrine&#x000a0;due to compensatory mechanisms. In dementia, progressive loss of neurons in the locus coeruleus and the subsequent decrease in norepinephrine release are thought to lead to compensatory upregulation of adrenergic receptors and hypersensitivity.<xref ref-type="bibr" rid="article-17289.r15">[15]</xref> Abnormal&#x000a0;activation of the orbitofrontal cortex and anterior cingulate cortex has been observed in patients with Alzheimer dementia.<xref ref-type="bibr" rid="article-17289.r15">[15]</xref>&#x000a0;In postmortem studies of patients with Alzheimer dementia, tau pathology has been associated with neuropsychiatric symptoms, including aggressive behavior.</p>
        <p>Multiple neurotransmitters have been postulated to be associated with aggression. Norepinephrine is implicated in aggression, as it is thought to be involved in the hyperactivation of the amygdala and other pathways involved in the "fight-or-flight" response. In addition to norepinephrine, dysregulation of dopaminergic, serotonergic, cholinergic, androgenic, and &#x003b3;-aminobutyric acid (GABA) systems has also been implicated in aggression.<xref ref-type="bibr" rid="article-17289.r29">[29]</xref>&#x000a0;Low levels of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in the cerebrospinal fluid have been associated with aggressive personality traits as well as suicide attempts using more violent means.<xref ref-type="bibr" rid="article-17289.r30">[30]</xref><xref ref-type="bibr" rid="article-17289.r31">[31]</xref>&#x000a0;A meta-analysis from 2020 showed that testosterone was associated with aggression, and it also found a small but statistically significant association between higher endogenous testosterone levels and aggression in men, but not in women.<xref ref-type="bibr" rid="article-17289.r32">[32]</xref></p>
        <p>The neurotransmitters involved in agitation can vary depending on the diagnosis.<xref ref-type="bibr" rid="article-17289.r28">[28]</xref> In psychosis and substance use, particularly stimulant-induced psychosis, agitation is often associated with a hyperdopaminergic state, with increased norepinephrine and reduced GABAergic tone. Dysregulated glutaminergic neurotransmission has also been implicated in agitation in psychosis, as glutamine is considered to modulate dopamine neurotransmission.</p>
        <p>Akathisia can lead to agitation and is believed to be modulated by increased dopamine blockade in striatal neurons due to antipsychotic medications, which also elevate central norepinephrine and further antagonize dopamine function.<xref ref-type="bibr" rid="article-17289.r33">[33]</xref>&#x000a0;Increased norepinephrine tone and decreased GABAergic inhibition have been proposed as contributing factors to agitation in panic disorder and generalized anxiety disorder. Agitation in these conditions is closely related to anxiety, which may be secondary to heightened hypothalamic-pituitary-adrenal axis activity.</p>
        <p>Two different serotonin models of agitation have been proposed in affective disorders.<xref ref-type="bibr" rid="article-17289.r28">[28]</xref>&#x000a0;The&#x000a0;"serotonin-sensitive" model applies to agitated depression or mania, where high catecholamine levels correspond with low serotonin levels. The "serotonin-resistant" model is characterized by extremely high arousal that drives aggression and agitation, associated with decreased GABAergic function and increased noradrenergic activity. GABA and serotonin pathways, which develop together, are involved in top-down modulation of the limbic system from the cortex, influencing agitation and other dysphoric reactions to the environment.<xref ref-type="bibr" rid="article-17289.r29">[29]</xref></p>
      </sec>
      <sec id="article-17289.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Before evaluating a patient with agitation, clinicians should ensure the environment is safe. They should ensure they can access the room's exit without interference. Staff should remain nearby while the clinician examines the patient in case of behavioral escalation. Clinicians should maintain a safe distance of at least 1 to 2 arm's length from the patient. Maintaining a calm demeanor and empathic approach may help reduce the risk of aggression.<xref ref-type="bibr" rid="article-17289.r34">[34]</xref><xref ref-type="bibr" rid="article-17289.r35">[35]</xref><xref ref-type="bibr" rid="article-17289.r36">[36]</xref></p>
        <p>Obtaining a history from an agitated individual can be difficult, as patients may be physically or verbally aggressive. Early recognition of risk is important, as are interventions targeted to the etiology of the agitation. The history and physical examination may first require nonpharmacological interventions (such as verbal de-escalation, changes in environment, and psychoeducation), medications, or physical restraint.</p>
        <p>Before considering physical restraints or medications, clinicians should first ensure the safety of the surroundings and attempt verbal de-escalation. If possible, they should move the patient to a quiet room with lower stimuli and dimmer lights and away from loud areas.<xref ref-type="bibr" rid="article-17289.r37">[37]</xref>&#x000a0;Verbal de-escalation can be aided by using a calm and even tone of voice, respecting personal space, using one person with one message, naming feelings, and appealing to the patient's wants or needs. In addition, setting limits and reinforcing appropriate behavior may be necessary. If medications are required, offering a choice to patients regarding medications or route of administration may increase their sense of control and reduce anxiety.&#x000a0;Some patients may respond to verbal de-escalation alone. After de-escalation, clinicians can attempt a focused evaluation, continuously monitoring for potential sudden outbursts of aggression during this process. They should avoid leading questions or making assumptions and initially focus on identifying the probable cause of the agitation.</p>
        <p>If patients do not respond to verbal de-escalation, oral medication should be offered next if patient or staff safety is not threatened. Oral medication can help engage the patient in their care and reduce a sense of coercion. If possible, collateral information should be obtained from any accompanying family member, friend, or witness while the medication takes effect and the patient is given time and space. If the patient remains agitated despite oral medication, a locked or unlocked seclusion room may provide an additional reduction in stimuli. Physical restraint and intramuscular medication may be necessary if safety remains a concern. When using seclusion, physical restraint, or intramuscular medication, the patient should be monitored closely and reassessed when it is safe to complete the evaluation and treatment plan.&#x000a0;</p>
        <p>In 2012, the American Association of Emergency Psychiatry Project BETA (Best Practices in the Evaluation and Treatment of Agitation in the emergency setting) published a consensus statement outlining recommendations for the medical evaluation and triage of patients with agitation,<xref ref-type="bibr" rid="article-17289.r38">[38]</xref>&#x000a0;which was updated in 2019 <xref ref-type="bibr" rid="article-17289.r39">[39]</xref>&#x000a0;and 2023.<xref ref-type="bibr" rid="article-17289.r37">[37]</xref>&#x000a0;Evaluating a patient with agitation differs based on whether the setting is nonmedical or medical. A brief history and vital signs should be obtained as safety allows.</p>
        <p>Immediate assessment for serious, possibly life-threatening conditions is recommended next. Symptoms that require immediate evaluation by a clinician include loss of memory, disorientation, severe headache, extreme muscle stiffness or weakness, heat intolerance, unintentional weight loss, new-onset psychosis, or difficulty breathing. Signs that require immediate evaluation by a clinician include any abnormal vital signs (blood pressure, pulse, oxygen saturation, or temperature), abnormal point-of-care glucose, any overt trauma, pupil asymmetry, slurred speech, incoordination, seizures, or hemiparesis.<xref ref-type="bibr" rid="article-17289.r38">[38]</xref>&#x000a0;In&#x000a0;a nonmedical setting, any of these signs or symptoms should lead to transfer to an emergency department or immediate clinician evaluation in a medical setting.</p>
        <p>In a nonmedical setting, if none of the above symptoms or signs are identified, assessing the level of agitation is recommended using psychometric scales such as the Overt Agitation Severity Scale (OASS) or the Behavioral Activity Rating Scale (BARS). Various screening tools and psychometric scales are available, and the choice of tool may depend on factors such as workflow, ease of use, setting, time constraints, and patient population. No current consensus favors one screening tool over another. Project BETA utilized BARS as a scale to triage patients.<xref ref-type="bibr" rid="article-17289.r38">[38]</xref> An individual who is difficult to arouse or cannot be aroused (BARS 1) should be transferred to a medical emergency department. If an individual does not respond to de-escalation, they should be moved to an acute care facility for further evaluation. If de-escalation is successful (BARS 5 or 6), or if the patient presents with a BARS of 4 and the presentation is consistent with their known psychiatric condition, routine management is recommended.</p>
        <p>History should be obtained from the patient and collateral sources (family, law enforcement, emergency medical services, and outpatient providers). This history should include details about previous agitation or violence, prior psychiatric hospitalizations, TBI, cognitive problems, borderline or antisocial personality disorder, interpersonal violence, and substance use.<xref ref-type="bibr" rid="article-17289.r37">[37]</xref></p>
        <p>The physical examination should include an assessment of the heart, lungs, abdomen, skin, and neurological system, as well as a mental status examination.<xref ref-type="bibr" rid="article-17289.r38">[38]</xref> For agitation due to a general medical condition, the examination should focus on head trauma, slurred speech, pupil asymmetry, motor problems, seizures, disorientation, hemiparesis, somnolence, muscle rigidity, myoclonus, and hyperreflexia.<xref ref-type="bibr" rid="article-17289.r38">[38]</xref>&#x000a0;In&#x000a0;cases of agitation due to alcohol or substance withdrawal or intoxication, the physical examination should assess for the odor of alcohol and evidence of drug injection, such as track marks, hallucinations, and seizures.<xref ref-type="bibr" rid="article-17289.r38">[38]</xref></p>
      </sec>
      <sec id="article-17289.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Identifying the etiology of agitation is a priority.&#x000a0;Initially, a point-of-care glucose test, oxygen saturation measurement, and urine toxicology screen are useful.&#x000a0;In cases of suspected substance intoxication or withdrawal, additional tests should include a urine toxicology screen, blood alcohol level, and liver function tests. When delirium is suspected, a complete blood count, comprehensive metabolic panel, urinalysis, urine toxicology screen, and head CT scan should be obtained to determine the etiology of delirium so the underlying cause can be treated.</p>
        <p>Other tests to consider include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy test: For all women of reproductive age.</p>
          </list-item>
          <list-item>
            <p>Ammonia: For hepatic encephalopathy.</p>
          </list-item>
          <list-item>
            <p>Creatinine kinase: For rhabdomyolysis, myopathy, and other muscle damage.</p>
          </list-item>
          <list-item>
            <p>Thyroid-stimulating hormone (TSH): For hypothyroidism or hyperthyroidism.</p>
          </list-item>
          <list-item>
            <p>Lactate: For sepsis.</p>
          </list-item>
          <list-item>
            <p>Acetaminophen and salicylate levels: For overdose.</p>
          </list-item>
          <list-item>
            <p>Urinalysis and urine culture: For urinary tract infection or ketosis.</p>
          </list-item>
          <list-item>
            <p>Lumbar puncture: For encephalitis or meningitis, syphilis, or cerebritis.</p>
          </list-item>
          <list-item>
            <p>Electrocardiogram (ECG): For QTc prolongation associated with overdose or cardiac disease.</p>
          </list-item>
        </list>
        <p>Further laboratory testing and radiographic evaluation should be guided by the identified underlying etiology.<xref ref-type="bibr" rid="article-17289.r40">[40]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17289.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of an agitated patient should prioritize diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment. Treatment recommendations should be guided by the underlying etiology of the agitation and the epidemiology of the local patient population.<xref ref-type="bibr" rid="article-17289.r41">[41]</xref>&#x000a0;This includes understanding the prevalence of specific substance use within the community and differentiating agitation resulting from intoxication or withdrawal.</p>
        <p>The best way to engage agitated patients is through noncoercive de-escalation, a complex intervention at the interface of psychotherapy, linguistic sciences, martial arts, the nursing profession, and law enforcement.<xref ref-type="bibr" rid="article-17289.r42">[42]</xref>&#x000a0;Patients may respond better to a particular healthcare provider for various reasons, in which case that provider can either lead or help facilitate the evaluation. Helping the patient feel that their concerns are being heard and addressed, and reflecting the patient's statements in their own words, can convey that the clinician is listening. Open-ended questions and active listening may de-escalate a volatile situation. If verbal de-escalation does not work, offering voluntary oral medications may be the next step. Seclusion may help calm the patient if excess environmental stimuli contribute to agitation. Patients should be allowed to self-regulate whenever possible without medications or physical restraints.</p>
        <p>In cases where all other interventions have failed or if patient or staff safety is threatened, involuntary medications may be necessary. When medications must be used, the goal should be to calm the patient so that they may safely engage in the medical evaluation. Clinicians should try to avoid sedating the patient if possible; however, treating for safety remains the primary goal. If a patient does experience sedation after medication administration, the patient should be closely monitored. Sedation from medications may also assist in recovery from agitation in specific cases, such as acute mania, which is a disorder of the sleep-wake cycle.<xref ref-type="bibr" rid="article-17289.r43">[43]</xref> In more severely agitated patients, especially those actively trying to hurt themselves or others, sedation may be emergently necessary. Using intramuscular injections for sedation can be termed a "chemical restraint" and is controversial.<xref ref-type="bibr" rid="article-17289.r9">[9]</xref><xref ref-type="bibr" rid="article-17289.r44">[44]</xref></p>
        <p>If agitation is mild or moderate, allowing the patient a choice regarding medication options may help reduce agitation. Oral medication administration should be prioritized over parenteral administration, although oral medications take effect more slowly. Institutions may have guidelines for the use of preferred medications. Agitation secondary to alcohol intoxication is best treated with an antipsychotic medication, whereas agitation secondary to alcohol withdrawal is best treated with a benzodiazepine. Evidence suggests that patients with neurocognitive disorders with agitation benefit from group activity-based interventions (recreation therapy), resident interventions (massage and touch therapy and music therapy), and person-centered care.<xref ref-type="bibr" rid="article-17289.r45">[45]</xref> &#x000a0;</p>
        <p>If a patient is a danger to themselves or others, they may require physical restraints. When physical restraints are implemented, close monitoring of the patient is necessary to ensure safety. Traumatic rhabdomyolysis has been associated with prolonged physical restraints, especially in individuals actively fighting against the restraints.<xref ref-type="bibr" rid="article-17289.r46">[46]</xref>&#x000a0;In&#x000a0;these cases, administering medications along with physical restraints may reduce the length of time restraints are needed and the subsequent risk of rhabdomyolysis. Other risks of physical restraints include pressure ulcers, asphyxiation, nerve and limb injuries, head injuries and intracranial hemorrhage, contractures, posttraumatic stress disorder, and reinforcement of past psychological traumas.<xref ref-type="bibr" rid="article-17289.r47">[47]</xref>&#x000a0;Physical&#x000a0;restraints may also induce hostility from the patient toward staff and contribute to future aggression. Patients who are restrained are more likely to have longer lengths of stay, increased risk of falls, decline in physical function, and increased risk of psychiatric comorbidities.<xref ref-type="bibr" rid="article-17289.r48">[48]</xref>&#x000a0;Physical restraints are the last resort and should be avoided if possible.</p>
        <p>
<bold>Pharmacological Management of Severe Agitation</bold>
</p>
        <p>The 2024 American College of Emergency Physicians (ACEP) evidence-based clinical policy for the treatment of patients in the emergency department with severe agitation recommends treatment with a combination of droperidol and midazolam or an atypical antipsychotic medication in combination with midazolam (Level B recommendation). The ACEP also recommends haloperidol alone or in combination with lorazepam (Level B recommendation).<xref ref-type="bibr" rid="article-17289.r49">[49]</xref>&#x000a0;Midazolam appears to have a more rapid onset than lorazepam. Olanzapine may have a more favorable profile than other atypical antipsychotic medications but should not be administered with benzodiazepines due to the risk of hypotension, bradycardia, and respiratory depression.<xref ref-type="bibr" rid="article-17289.r49">[49]</xref>&#x000a0;In situations in the emergency department where the safety of the patient, bystanders, or staff is a concern, the ACEP recommends considering intravenous or intramuscular ketamine to rapidly treat severe agitation (Level C recommendation), noting the risks of laryngospasm and hypersalivation with an infrequent need for intubation due to these adverse effects.<xref ref-type="bibr" rid="article-17289.r49">[49]</xref></p>
        <p>According to the ACEP review, due to the lack of evidence, no recommendations can be made regarding the use of specific agents in out-of-hospital settings or for patients aged 65 or older.<xref ref-type="bibr" rid="article-17289.r49">[49]</xref>&#x000a0;Both typical and atypical antipsychotic medications have black box warnings indicating that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. The ACEP acknowledges that droperidol carries a black box warning for QT prolongation, requiring ECG monitoring of the QT interval before administration and continuing for 2 to 3 hours after completing treatment. However, the ACEP review demonstrated an overall favorable safety profile for droperidol when used for sedation of agitated patients in the emergency department.<xref ref-type="bibr" rid="article-17289.r49">[49]</xref></p>
        <p>The Society of Critical Care Medicine (SCCM) 2018 Practice Guidelines suggest not routinely using haloperidol to treat delirium, as the evidence indicates that the use of haloperidol or an atypical antipsychotic medication is not associated with a shorter duration of delirium, mechanical ventilation, ICU length of stay, or decreased mortality. Despite the lack of evidence, short-term use of haloperidol or an atypical antipsychotic medication may be considered for agitated patients who may physically harm themselves or others. The SCCM conditionally recommends using dexmedetomidine for delirium in mechanically ventilated adults where agitation is precluding weaning/extubation.<xref ref-type="bibr" rid="article-17289.r35">[35]</xref> &#x000a0;</p>
        <p>The American Psychiatric Association (APA) Practice Guideline (2016) recommends considering nonemergency antipsychotic medication only for managing "severe, dangerous, and/or significantly distressing agitation or psychosis."<xref ref-type="bibr" rid="article-17289.r50">[50]</xref>&#x000a0;In addition, the APA recommends reviewing the clinical response to nonpharmacological interventions before using nonemergency antipsychotics for agitation and constantly assessing the benefit-to-harm ratio.</p>
        <p>Identifying drugs that may contribute to agitation is the first step in the pharmacological treatment of patients with neurocognitive disorders. Anticholinergic drugs may cause delirium, antipsychotic medications may cause neuroleptic malignant syndrome, serotonergic drugs may cause serotonin syndrome, and stimulants may cause hyperarousal. Cholinesterase inhibitors and memantine may reduce agitation in people with Alzheimer disease or Lewy body disease.<xref ref-type="bibr" rid="article-17289.r45">[45]</xref></p>
        <p>The International Psychogeriatric Association (IPA) consensus algorithm (2024) emphasizes the importance of ongoing psychosocial interventions for patients with neurocognitive disorders and agitation. IPA suggests various pharmacological treatments based on severity and circumstances, noting that there are no FDA-approved medications specifically for agitation in the United States.<xref ref-type="bibr" rid="article-17289.r45">[45]</xref>&#x000a0;Agitation&#x000a0;that occurs at night or with "sundowning" can be treated with trazodone or dual orexin receptor antagonists such as suvorexant and lemborexant. Mild-to-moderate agitation or agitation with mood features can be treated with citalopram. In contrast, moderate-to-severe agitation can be treated with atypical antipsychotic medications (avoided in patients with Lewy body disease or Parkinson disease), carbamazepine, gabapentin, prazosin, dextromethorphan/quinidine, nabilone, or a combination of these medications. If agitation is extreme, intramuscular olanzapine or aripiprazole, or electroconvulsive therapy can reduce agitation. For patients with neurocognitive disorders with pain, such as hospice patients, morphine, delta-9-tetracannabinol, dronabinol, and cannabidiol can be beneficial.<xref ref-type="bibr" rid="article-17289.r45">[45]</xref> &#x000a0;&#x000a0;&#x000a0;</p>
        <p>Benzodiazepines are the first-line therapy for agitated patients with alcohol withdrawal or central nervous system stimulant toxicity from cocaine or amphetamines.<xref ref-type="bibr" rid="article-17289.r41">[41]</xref>&#x000a0;The American Society of Addiction Medicine (ASAM) recommends avoiding antipsychotic monotherapy for agitation in alcohol withdrawal, as it may lead to delirium tremens and an increased risk of complicated withdrawal.<xref ref-type="bibr" rid="article-17289.r51">[51]</xref> Antipsychotic medications also reduce the seizure threshold.<xref ref-type="bibr" rid="article-17289.r52">[52]</xref> The World Federation of Societies of Biological Psychiatry (WFSBP) recommends that for agitation associated with alcohol intoxication rather than withdrawal, antipsychotics are preferred over benzodiazepines, which can potentiate the effects of alcohol and increase the risk of respiratory depression.<xref ref-type="bibr" rid="article-17289.r41">[41]</xref></p>
        <p>In patients with autism spectrum disorder and agitation, risperidone and aripiprazole are the only FDA-approved medications.<xref ref-type="bibr" rid="article-17289.r53">[53]</xref>&#x000a0;Both medications have been studied primarily in children and adolescents, and further research is needed to confirm their effectiveness. Risperidone was approved by the FDA in 2007 for patients aged 5 to 17, following short-term trials demonstrating benefits in reducing aggression, self-injury, temper tantrums, and mood swings, with over 90% of participants aged 12 or younger. Aripiprazole is also FDA-approved for treating irritability associated with autism spectrum disorder in children and adolescents aged 6 to 17.</p>
      </sec>
      <sec id="article-17289.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses of agitation can be broadly classified as physical illness and delirium, neurocognitive disorders, substance use and withdrawal, and psychiatric and developmental conditions (see <bold>Table</bold> below).<xref ref-type="bibr" rid="article-17289.r54">[54]</xref></p>
        <table-wrap id="article-17289.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Examples of Differential Diagnoses of Agitation</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 35px;">
                <td style="vertical-align: middle; height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p><bold>System</bold></p>
</td>
                <td style="vertical-align: middle; height: 35px; width: 659.275px;" rowspan="1" colspan="1">
<bold>Differential Diagnosis</bold>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="vertical-align: middle; height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Constitutional</p>
</td>
                <td style="vertical-align: middle; height: 35px; width: 659.275px;" rowspan="1" colspan="1">Insomnia, pain, hypothermia, hyperthermia, and terminal illness.</td>
              </tr>
              <tr style="height: 35px;">
                <td style="vertical-align: middle; height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Neurological</p>
</td>
                <td style="vertical-align: middle; height: 35px; width: 659.275px;" rowspan="1" colspan="1">TBI, neurocognitive disorders, intracranial hemorrhage, stroke, transient ischemic attack, encephalopathy, epilepsy, autoimmune encephalitis, and seizure.</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Infectious</p>
</td>
                <td style="height: 35px; width: 659.275px;" rowspan="1" colspan="1">Meningitis, encephalitis, sepsis, urinary tract infection, pneumonia, cellulitis, and necrotizing fasciitis.</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Cardiopulmonary&#x000a0;</p>
</td>
                <td style="height: 35px; width: 659.275px;" rowspan="1" colspan="1">Myocardial infarction, heart failure, arrhythmia, pulmonary embolism, respiratory failure, hypoxia, and hypoxemia.</td>
              </tr>
              <tr style="height: 49px;">
                <td style="height: 49px; width: 111.125px;" rowspan="1" colspan="1">
<p>Metabolic and endocrine</p>
</td>
                <td style="height: 49px; width: 659.275px;" rowspan="1" colspan="1">Diabetic&#x000a0;ketoacidosis,&#x000a0;electrolyte disturbances, chronic malnutrition, hypoglycemia,&#x000a0;hyperthyroidism, myxedema, and hyperparathyroidism.</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Gastrointestinal&#x000a0;</p>
</td>
                <td style="height: 35px; width: 659.275px;" rowspan="1" colspan="1">Ileus, inflammatory bowel disease,&#x000a0;gastrointestinal obstruction, and constipation.</td>
              </tr>
              <tr style="height: 40px;">
                <td style="height: 40px; width: 111.125px;" rowspan="1" colspan="1">
<p>Toxicological</p>
</td>
                <td style="height: 40px; width: 659.275px;" rowspan="1" colspan="1">Environmental toxins and medication-related adverse effects, including anticholinergic medications, akathisia, cholinergic toxicity, neuroleptic malignant syndrome, serotonin syndrome, and medication interactions, and polypharmacy.</td>
              </tr>
              <tr style="height: 49px;">
                <td style="height: 49px; width: 111.125px;" rowspan="1" colspan="1">
<p>Hematologic and Oncologic</p>
</td>
                <td style="height: 49px; width: 659.275px;" rowspan="1" colspan="1">Anemia, leukemia, multiple myeloma, primary brain tumors, brain metastases, and paraneoplastic syndrome.</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 111.125px;" rowspan="1" colspan="1">
<p>Renal</p>
</td>
                <td style="height: 35px; width: 659.275px;" rowspan="1" colspan="1">Acute and chronic kidney disease, end-stage renal disease, including non-adherence to dialysis, and uremia.</td>
              </tr>
              <tr style="height: 68px;">
                <td style="height: 68px; width: 111.125px;" rowspan="1" colspan="1">
<p>Psychiatric</p>
</td>
                <td style="height: 68px; width: 659.275px;" rowspan="1" colspan="1">Acute psychosis from schizophrenia spectrum disorders, acute mania from bipolar spectrum disorders, agitated depression, excited catatonia, anxiety and&#x000a0;panic disorders, acute exacerbation of posttraumatic stress disorder, personality disorders, conduct disorder, attention-deficit/hyperactivity disorder, intermittent explosive disorder, dissociative disorder, and postpartum psychosis.</td>
              </tr>
              <tr style="height: 49px;">
                <td style="height: 49px; width: 111.125px;" rowspan="1" colspan="1">
<p>Substance</p>
</td>
                <td style="height: 49px; width: 659.275px;" rowspan="1" colspan="1">
<p>Substance intoxication (alcohol, cannabis, cocaine, stimulants, hallucinogens, and inhalants), substance withdrawal (nicotine, alcohol, benzodiazepines, and barbituates), and Wernicke-Korsakoff syndrome.&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Reference for&#x000a0;the Table.<xref ref-type="bibr" rid="article-17289.r37">[37]</xref></p>
      </sec>
      <sec id="article-17289.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Agitation is a medical and psychiatric emergency with a broad differential diagnosis. The prognosis depends on the swift identification of the underlying cause, prompt treatment, and maintaining a safe environment to prevent injury to patients, bystanders, and staff. In the short term, reducing stress, improving sleep quality, and addressing the patient's needs can often lead to better outcomes. Agitation related to substance use may resolve with detoxification and treatment of withdrawal symptoms. Patients with altered mental status who exhibit generalized slowing on electroencephalogram may have a worse prognosis.<xref ref-type="bibr" rid="article-17289.r55">[55]</xref>&#x000a0;In&#x000a0;the ICU, agitated patients with delirium tend to have a worse prognosis compared to those without agitation.<xref ref-type="bibr" rid="article-17289.r56">[56]</xref></p>
      </sec>
      <sec id="article-17289.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Agitation is a medical and psychiatric emergency that heightens the risk of injury to patients, bystanders, and staff. Complications associated with agitation include falls, removal of indwelling catheters and tubes, and restraint-related injuries. Physical restraints can lead to dislocations, fractures, skin abrasions, head injuries, and rhabdomyolysis, especially if individuals remain agitated and resist the restraints. The use of sedating medications in conjunction with physical restraints can help mitigate these risks.</p>
      </sec>
      <sec id="article-17289.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education after an acute agitation episode can help patients understand the underlying causes and potentially reduce future risks. The effectiveness of patient education varies depending on the etiology of the agitation. Major neurocognitive disorders, autism spectrum disorders, and delirium may not be easily preventable through patient education alone, as agitation can recur due to chronic medical issues and frontal lobe dysfunction. However, outpatient behavioral interventions and treatments can help mitigate agitation and aggression in patients with autism spectrum disorders.<xref ref-type="bibr" rid="article-17289.r57">[57]</xref>&#x000a0;</p>
        <p>For individuals with psychiatric disorders such as schizophrenia, bipolar disorder, and substance use disorders, patient education should focus on the importance of treatment compliance and provide detailed information about medications. For individuals with personality disorders, debriefing the causes of emotional dysregulation and using techniques such as behavioral chain analysis to identify predisposing, precipitating, perpetuating, and protective factors can help patients reflect on the episode systematically and develop strategies to prevent future occurrences.</p>
      </sec>
      <sec id="article-17289.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key considerations regarding agitation include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Agitation is a medical and psychiatric emergency that&#x000a0;increases the risk of injury to patients, bystanders, and staff.</p>
          </list-item>
          <list-item>
            <p>Management should prioritize diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment.</p>
          </list-item>
          <list-item>
            <p>Collateral information should be collected to help identify the underlying cause of agitation.</p>
          </list-item>
          <list-item>
            <p>Verbal de-escalation and minimizing environmental stimuli are initial steps in managing agitation.</p>
          </list-item>
          <list-item>
            <p>If calming medications are required, clinicians should involve the patient in choosing the medication and route of administration to enhance their sense of control.</p>
          </list-item>
          <list-item>
            <p>Medications and seclusion are the next steps in treating individuals with severe agitation.</p>
          </list-item>
          <list-item>
            <p>Physical restraints should be avoided unless essential for the safety of the patient, bystanders, and staff.</p>
          </list-item>
          <list-item>
            <p>When required, physical restraints should be used for the minimal time necessary. The patient should be monitored closely, and efforts should be made to transition them to a less restrictive approach as soon as possible.</p>
          </list-item>
          <list-item>
            <p>Agitation management, including the use of calming medications, should be tailored to the individual, the setting, and the underlying etiology.</p>
          </list-item>
          <list-item>
            <p>Both the adverse and beneficial effects of medications should be closely monitored to ensure patient safety and optimize outcomes.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17289.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Multidisciplinary treatment teams should ideally be trained in safely managing agitation and assaultive behaviors with minimal necessary interventions.<xref ref-type="bibr" rid="article-17289.r58">[58]</xref><xref ref-type="bibr" rid="article-17289.r59">[59]</xref>&#x000a0;Nonviolent crisis intervention techniques have been associated with a reduction in emergency security team involvement.<xref ref-type="bibr" rid="article-17289.r60">[60]</xref>&#x000a0;Additionally, training in the management of agitation may improve the likelihood of staff being able to complete thorough assessments of these challenging patients.<xref ref-type="bibr" rid="article-17289.r61">[61]</xref><xref ref-type="bibr" rid="article-17289.r62">[62]</xref></p>
        <p>The most effective approach to engaging agitated patients is through noncoercive de-escalation, a multifaceted intervention that combines elements of psychotherapy, linguistic sciences, martial arts, nursing, and law enforcement.<xref ref-type="bibr" rid="article-17289.r42">[42]</xref> Clinicians&#x000a0;can enhance these skills by role-playing and practicing impromptu scenarios with colleagues, with further refinement gained through real-world experience.&#x000a0;Because the definition and use of the term "agitation" can vary, the clinical team should identify patient-specific behaviors to clarify how agitation is defined for that particular patient. Achieving consensus on this definition will help guide the management plan effectively.<xref ref-type="bibr" rid="article-17289.r3">[3]</xref>&#x000a0;</p>
        <p>Agitation is common among hospitalized patients and requires a collaborative approach from the multidisciplinary team. The interprofessional healthcare team should include&#x000a0;psychiatry, internal medicine, physician assistants, nurse practitioners, nursing and nursing assistants, neurology, applicable medical subspecialists, pharmacists, and hospital security. The involvement&#x000a0;of a multidisciplinary&#x000a0;healthcare team is essential&#x000a0;in&#x000a0;rapport building, de-escalation, limit setting, medication administration, and&#x000a0;ongoing assessment of the value of various interventions. Only team members trained in&#x000a0;physical crisis intervention should attempt to intervene if physical force is necessary. Following the treatment of an agitated patient, the team should debrief to process emotions about the situation, identify patterns in patient behavior, and discuss strategies for improving ongoing treatment.</p>
      </sec>
      <sec id="article-17289.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17289&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17289">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/agitation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17289">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17289/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17289">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17289.s16">
        <title>References</title>
        <ref id="article-17289.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ducci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galluzzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Berardis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2021</year>
            <month>Apr</month>
            <day>20</day>
            <volume>18</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">33924111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez-Raga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Sciascio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Florea</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Garriga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Margariti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacciardi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Papageorgiou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rivollier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Royuela</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Safont</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scharfetter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skagen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tajima-Pozo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vidailhet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>1st International Experts' Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation.</article-title>
            <source>Front Psychiatry</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">29535649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Aggression and Agitation in Dementia.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY</issue>
            <fpage>783</fpage>
            <page-range>783-803</page-range>
            <pub-id pub-id-type="pmid">29851878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Managing acute agitation and aggression in the world of drug shortages.</article-title>
            <source>Ment Health Clin</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>334</fpage>
            <page-range>334-346</page-range>
            <pub-id pub-id-type="pmid">34824958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fairburn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gedling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Natural history of aggressive behaviour in dementia.</article-title>
            <source>Int J Geriatr Psychiatry</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>541</fpage>
            <page-range>541-8</page-range>
            <pub-id pub-id-type="pmid">10440974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Morgia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Testa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lodi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of Light Treatment on Sleep, Cognition, Mood, and Behavior in Alzheimer's Disease: A Systematic Review.</article-title>
            <source>Dement Geriatr Cogn Disord</source>
            <year>2018</year>
            <volume>46</volume>
            <issue>5-6</issue>
            <fpage>371</fpage>
            <page-range>371-384</page-range>
            <pub-id pub-id-type="pmid">30537760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferreyro</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Doufl&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Supportive Care of Patients on Mechanical Ventilation.</article-title>
            <source>Respir Care</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>1567</fpage>
            <page-range>1567-1574</page-range>
            <pub-id pub-id-type="pmid">30467227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haskell</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Frankel</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Rotondo</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Agitation.</article-title>
            <source>AACN Clin Issues</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-50</page-range>
            <pub-id pub-id-type="pmid">9313372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Driver</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The Characteristics and Prevalence of Agitation in an Urban County Emergency Department.</article-title>
            <source>Ann Emerg Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-370</page-range>
            <pub-id pub-id-type="pmid">30031556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ram&#x000ed;rez Echeverr&#x000ed;a</surname>
                <given-names>MDL</given-names>
              </name>
              <name>
                <surname>Schoo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Delirium</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">29261982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sili&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x0010c;ulo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vukojevi&#x00107;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brumen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ostoji&#x00107;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Approach to Emergencies in Schizophrenia in University Hospital "Vrap&#x0010d;e".</article-title>
            <source>Psychiatr Danub</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>Suppl 4</issue>
            <fpage>203</fpage>
            <page-range>203-207</page-range>
            <pub-id pub-id-type="pmid">29864761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e9;guin</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The frontal lobe and aggression.</article-title>
            <source>Eur J Dev Psychol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>05</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-119</page-range>
            <pub-id pub-id-type="pmid">24976846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brower</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatry of frontal lobe dysfunction in violent and criminal behaviour: a critical review.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>720</fpage>
            <page-range>720-6</page-range>
            <pub-id pub-id-type="pmid">11723190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pajonk</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biedler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luiz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Madler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>360</fpage>
            <page-range>360-6</page-range>
            <pub-id pub-id-type="pmid">18585541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrarini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dono</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rispoli</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Pietro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Digiovanni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ajdinaj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Speranza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Granzotto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frazzini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pilotto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padovani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Onofrj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sensi</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonanni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>644317</fpage>
            <pub-id pub-id-type="pmid">33935943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauhuis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulders</surname>
                <given-names>AJMJ</given-names>
              </name>
              <name>
                <surname>Koopmans</surname>
                <given-names>RTCM</given-names>
              </name>
            </person-group>
            <article-title>The course of neuropsychiatric symptoms in institutionalized patients with young onset dementia.</article-title>
            <source>Aging Ment Health</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <page-range>439-444</page-range>
            <pub-id pub-id-type="pmid">30499335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arroyo-Novoa</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Figueroa-Ramos</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Puntillo</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Occurrence and Practices for Pain, Agitation, and Delirium in Intensive Care Unit Patients.</article-title>
            <source>P R Health Sci J</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-162</page-range>
            <pub-id pub-id-type="pmid">31536628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burk</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Grap</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sessler</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Agitation onset, frequency, and associated temporal factors in critically ill adults.</article-title>
            <source>Am J Crit Care</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-304</page-range>
            <pub-id pub-id-type="pmid">24986170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chanques</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Altairac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sebbane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vergne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perrigault</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Eledjam</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>A prospective study of agitation in a medical-surgical ICU: incidence, risk factors, and outcomes.</article-title>
            <source>Chest</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>2749</fpage>
            <page-range>2749-57</page-range>
            <pub-id pub-id-type="pmid">16236951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gracia Canales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blanthorn-Hazell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Craciun Boldeanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia.</article-title>
            <source>BMC Psychiatry</source>
            <year>2018</year>
            <month>Apr</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <pub-id pub-id-type="pmid">29661160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Theriault</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Rosenheck</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Increasing Emergency Department Visits for Mental Health Conditions in the United States.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2020</year>
            <month>Jul</month>
            <day>28</day>
            <volume>81</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32726001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sachs</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>A review of agitation in mental illness: burden of illness and underlying pathology.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2006</year>
            <volume>67 Suppl 10</volume>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">16965190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fazel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug Use Disorders and Violence: Associations With Individual Drug Categories.</article-title>
            <source>Epidemiol Rev</source>
            <year>2020</year>
            <month>Jan</month>
            <day>31</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-116</page-range>
            <pub-id pub-id-type="pmid">33005950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williamson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Perreault</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Charbonney</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lamontagne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Potvin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gigu&#x000e8;re</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis.</article-title>
            <source>Syst Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>17</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <pub-id pub-id-type="pmid">27855720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baksh</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hassiotis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TLB</given-names>
              </name>
              <collab>PETAL Investigators</collab>
              <name>
                <surname>Strydom</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Aggressive challenging behavior in adults with intellectual disability: An electronic register-based cohort study of clinical outcome and service use.</article-title>
            <source>Eur Psychiatry</source>
            <year>2022</year>
            <month>Nov</month>
            <day>02</day>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>e74</fpage>
            <pub-id pub-id-type="pmid">36321353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delli Pizzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padulo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brancucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bubbico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Edden</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franciotti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manippa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marzoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Onofrj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sepede</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tartaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tommasi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Puglisi-Allegra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonanni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>GABA content within the ventromedial prefrontal cortex is related to trait anxiety.</article-title>
            <source>Soc Cogn Affect Neurosci</source>
            <year>2016</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>758</fpage>
            <page-range>758-66</page-range>
            <pub-id pub-id-type="pmid">26722018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goyer</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Andreason</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Compton-Toth</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Positron-emission tomography and personality disorders.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">8179791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindenmayer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology of agitation.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2000</year>
            <volume>61 Suppl 14</volume>
            <fpage>5</fpage>
            <page-range>5-10</page-range>
            <pub-id pub-id-type="pmid">11154018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>CWT</given-names>
              </name>
              <name>
                <surname>Hodzic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Current Understanding of the Neurobiology of Agitation.</article-title>
            <source>West J Emerg Med</source>
            <year>2020</year>
            <month>Jul</month>
            <day>02</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>841</fpage>
            <page-range>841-848</page-range>
            <pub-id pub-id-type="pmid">32726254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siever</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trestman</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>The serotonin system and aggressive personality disorder.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>8 Suppl 2</volume>
            <fpage>33</fpage>
            <page-range>33-9</page-range>
            <pub-id pub-id-type="pmid">8201245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>New</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Trestman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mitropoulou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Benishay</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Coccaro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siever</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Serotonergic function and self-injurious behavior in personality disorder patients.</article-title>
            <source>Psychiatry Res</source>
            <year>1997</year>
            <month>Mar</month>
            <day>03</day>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-26</page-range>
            <pub-id pub-id-type="pmid">9080541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geniole</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>McVittie</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Purcell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carr&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Is testosterone linked to human aggression? A meta-analytic examination of the relationship between baseline, dynamic, and manipulated testosterone on human aggression.</article-title>
            <source>Horm Behav</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>123</volume>
            <fpage>104644</fpage>
            <pub-id pub-id-type="pmid">31785281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McAllister</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Caudle</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>2045125320937575</fpage>
            <pub-id pub-id-type="pmid">32922732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maximous</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>JLY</given-names>
              </name>
            </person-group>
            <article-title>Pain, agitation and delirium assessment and management in a community medical-surgical ICU: results from a prospective observational study and nurse survey.</article-title>
            <source>BMJ Open Qual</source>
            <year>2018</year>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e000413</fpage>
            <pub-id pub-id-type="pmid">30397663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devlin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Skrobik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>G&#x000e9;linas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Needham</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Slooter</surname>
                <given-names>AJC</given-names>
              </name>
              <name>
                <surname>Pandharipande</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Weinhouse</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Nunnally</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Balas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>van den Boogaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosma</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Brummel</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Chanques</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Denehy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drouot</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kho</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kress</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lanphere</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McKinley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Payen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pun</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Puntillo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Riker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BRH</given-names>
              </name>
              <name>
                <surname>Shehabi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Szumita</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Centofanti</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nikayin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misak</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kiedrowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alhazzani</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>1532</fpage>
            <page-range>1532-1548</page-range>
            <pub-id pub-id-type="pmid">30113371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Souza</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Azzolin</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Multiprofessional care for delirium patients in intensive care: integrative review.</article-title>
            <source>Rev Gaucha Enferm</source>
            <year>2018</year>
            <month>Aug</month>
            <day>02</day>
            <volume>39</volume>
            <fpage>e20170157</fpage>
            <pub-id pub-id-type="pmid">30088606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mroczkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nordstrom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Updates in the Assessment and Management of Agitation.</article-title>
            <source>Focus (Am Psychiatr Publ)</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-45</page-range>
            <pub-id pub-id-type="pmid">37205032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordstrom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zun</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stiebel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bregman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup.</article-title>
            <source>West J Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">22461915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roppolo</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation).</article-title>
            <source>J Am Coll Emerg Physicians Open</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>5</issue>
            <fpage>898</fpage>
            <page-range>898-907</page-range>
            <pub-id pub-id-type="pmid">33145538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeller</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rhoades</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Systematic reviews of assessment measures and pharmacologic treatments for agitation.</article-title>
            <source>Clin Ther</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-25</page-range>
            <pub-id pub-id-type="pmid">20399981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Searles Quick</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Kalapatapu</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Which Emergent Medication Should I Give Next? Repeated Use of Emergent Medications to Treat Acute Agitation.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>750686</fpage>
            <pub-id pub-id-type="pmid">34950067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richmond</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fishkind</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Holloman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rifai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup.</article-title>
            <source>West J Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-25</page-range>
            <pub-id pub-id-type="pmid">22461917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodwin</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Abbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlaepfer</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Grunze</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Licht</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bellivier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fountoulakis</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Altamura</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pitchot</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>&#x000c5;gren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holsboer-Trachsler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>2285</fpage>
            <page-range>2285-99</page-range>
            <pub-id pub-id-type="pmid">22014287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Currier</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>The controversy over "chemical restraint" in acute care psychiatry.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-70</page-range>
            <pub-id pub-id-type="pmid">15985915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gerritsen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grossberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lanct&#x000f4;t</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lapid</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mintzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Splaine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.</article-title>
            <source>Int Psychogeriatr</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-262</page-range>
            <pub-id pub-id-type="pmid">36876335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huerta-Alard&#x000ed;n</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Varon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marik</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.</article-title>
            <source>Crit Care</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-69</page-range>
            <pub-id pub-id-type="pmid">15774072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunawardena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smithard</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>The Attitudes Towards the Use of Restraint and Restrictive Intervention Amongst Healthcare Staff on Acute Medical and Frailty Wards-A Brief Literature Review.</article-title>
            <source>Geriatrics (Basel)</source>
            <year>2019</year>
            <month>Sep</month>
            <day>04</day>
            <volume>4</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31487923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spennato</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lerjen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siegwart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schuetz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Struja</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, Risk Factors and Outcomes Associated with Physical Restraint in Acute Medical Inpatients over 4 Years-A Retrospective Cohort Study.</article-title>
            <source>Geriatrics (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>17</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36826357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Severe Agitation</collab>
              <name>
                <surname>Thiessen</surname>
                <given-names>MEW</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hatten</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Haukoos</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <collab>Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee)</collab>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Byyny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gemme</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gerardo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hatten</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Haukoos</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kaji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Promes</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Slivinski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Thiessen</surname>
                <given-names>MEW</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Westafer</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cantrill</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Finnell</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vandertulip</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023.</article-title>
            <source>Ann Emerg Med</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e30</page-range>
            <pub-id pub-id-type="pmid">38105109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reus</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Eyler</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hilty</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Horvitz-Lennon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jibson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Wills</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rhoads</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2016</year>
            <month>May</month>
            <day>01</day>
            <volume>173</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-6</page-range>
            <pub-id pub-id-type="pmid">27133416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>14</volume>
            <issue>3S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-72</page-range>
            <pub-id pub-id-type="pmid">32511109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faustmann</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Paschali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kojda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schilbach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kamp</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Antipsychotic Treatment of Alcohol Withdrawal Syndrome with Focus on Delirium Tremens: a Systematic Review].</article-title>
            <source>Fortschr Neurol Psychiatr</source>
            <year>2023</year>
            <month>Mar</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">36958342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subramanyam</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chavda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Autism Spectrum Disorders.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>Suppl 2</issue>
            <fpage>254</fpage>
            <page-range>254-269</page-range>
            <pub-id pub-id-type="pmid">30745701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raveesh</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Munoli</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Gowda</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Assessment and Management of Agitation in Consultation-Liaison Psychiatry.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>Suppl 2</issue>
            <fpage>S484</fpage>
            <page-range>S484-S498</page-range>
            <pub-id pub-id-type="pmid">35602364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimchi</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Neelagiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whitt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sagi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gadbois</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Groothuysen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Westover</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Clinical EEG slowing correlates with delirium severity and predicts poor clinical outcomes.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Sep</month>
            <day>24</day>
            <volume>93</volume>
            <issue>13</issue>
            <fpage>e1260</fpage>
            <page-range>e1260-e1271</page-range>
            <pub-id pub-id-type="pmid">31467255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chevrolet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jolliet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical review: agitation and delirium in the critically ill--significance and management.</article-title>
            <source>Crit Care</source>
            <year>2007</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <pub-id pub-id-type="pmid">17521456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Srivorakiat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wink</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Pedapati</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Aggression in autism spectrum disorder: presentation and treatment options.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>1525</fpage>
            <page-range>1525-38</page-range>
            <pub-id pub-id-type="pmid">27382295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calabro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of training designed to prevent and manage patient violence.</article-title>
            <source>Issues Ment Health Nurs</source>
            <year>2002</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-15</page-range>
            <pub-id pub-id-type="pmid">11887608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Axer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beckett</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Training in preventing assaultive behaviors for psychiatric professionals].</article-title>
            <source>Psychiatr Pol</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-41</page-range>
            <pub-id pub-id-type="pmid">9816901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillam</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Nonviolent crisis intervention training and the incidence of violent events in a large hospital emergency department: an observational quality improvement study.</article-title>
            <source>Adv Emerg Nurs J</source>
            <year>2014</year>
            <season>Apr-Jun</season>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-88</page-range>
            <pub-id pub-id-type="pmid">24785670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Craufurd</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Drazinic</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Edmondson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Kammen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Loy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Priller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.</article-title>
            <source>J Huntingtons Dis</source>
            <year>2018</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>355</fpage>
            <page-range>355-366</page-range>
            <pub-id pub-id-type="pmid">30040737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17289.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lofchy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Agitation and CANMAT and ISBD 2018 Bipolar Guidelines.</article-title>
            <source>Bipolar Disord</source>
            <year>2018</year>
            <month>Jul</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30022579</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
